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Introduction
Calprotectin is a neutrophil derived protein that binds cal-
cium and belongs to the S100 family. It can be quantified
in feces and has become established as a marker of gut
inflammation, where increased levels are a direct result of
neutrophil migration into the gut lumen across the
inflamed mucosa. Since subclinical gut inflammation is
present in the majority of adult and pediatric spondyloar-
thritis patients, fecal calprotectin (fcal) is emerging as pos-
sible noninvasive biomarker. There is strong evidence
supporting the role of the VSL-3 probiotic in decreasing
fcal, thus promoting and maintaining remission in patients
with inflammatory bowel disease (IBD), but very little is
known of its potential effects on disease activity in chil-
dren with undifferentiated spondyloarthritis (ERA).
Objectives
To assess the effect of the VSL-3 probiotic on fcal levels,
clinical symptoms and disease activity of children with
undifferentiated spondyloarthritis (ERA).
Methods
Sixteen patients diagnosed with ERA, according to the
ILAR criteria, were treated with VSL-3, in addition to stan-
dard therapy (NSAID’s and DMARD’s). All patients were
negative for gastrointestinal (GI) symptoms, and/or poor
growth. All four ankylosing spondylitis patients received
biologics; two were treated with adalimumab and further
two with infliximab. In addition to general clinical data,
patients completed the BASFI and BASDAI questioners,
ESR and CRP were obtained, and fcal was measured by the
Calprest ELISA method (Eurospital Spa, Italy). After VSL-3
was introduced, two follow up visits were scheduled; the
first after one month and the second after three months. At
the three month visit a second fcal value was obtained, and
BASFI and BASDAI were reevaluated.
Results
The baseline mean fcal level was 52,3 mg/kg (normal <
50 mg/kg). Nine patients have completed all scheduled
visits to date, and eight out of those nine had markedly
decreased fcal levels (mean value 15,6 mg/kg). The BASFI
index was decreased in seven patients and the BASDAI
index in eight patients. At the follow-up visit, none of the
patients were found to have developed GI symptoms or
other signs and symptoms suggestive of IBD.
Conclusion
VSL-3 is emerging as a possible potent adjuvant therapy
in children and adults with IBD thus encouraging its use
in patients with ERA. To our knowledge our study is the
first in evaluating the effects of VSL-3, as adjuvant ther-
apy, on disease activity in ERA patients. Preliminary data
suggest that the use of VSL-3 can decrease fcal levels, and
together with standard therapy can improve clinical
symptoms and decrease disease activity in patients with
ERA. A larger patient cohort is needed to confirm VSL-3
efficacy in ERA patients.
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